Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GCLC | P48506 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL9401153 | 0.84 | FOLH1 (0.58) | CA2MAPK1FOLH1 | |
| SCHEMBL21629697 | 0.84 | CHRM1 (0.73) | CA2MAPK1CHRM1AKR1A1CHRM3 | |
| SCHEMBL25853752 | 0.83 | ALDH1A1 (0.43) | CA2MAPK1CHRM1AKR1A1CHRM3 | |
| SCHEMBL1722576 | 0.83 | FOLH1 (0.62) | CA2MAPK1FOLH1 | |
| SCHEMBL9816375 | 0.82 | CA2 (0.54) | CA2MAPK1CHRM1AKR1A1CHRM3 | |
| SCHEMBL125406 | 0.82 | CA2 (0.71) | CA2MAPK1CHRM1AKR1A1CHRM3 | |
| SCHEMBL10430532 | 0.81 | FOLH1 (0.61) | FOLH1LMNASLC15A2 | |
| SCHEMBL28555785 | 0.81 | FOLH1 (0.43) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL29103756 | 0.81 | FOLH1 (0.60) | CA2MAPK1FOLH1 | |
| Hydrochloric Acid SCHEMBL5841423 | 0.81 | FOLH1 (0.60) | CA2MAPK1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2822050-B1 | CHARGE-TRANSPORTING VARNISH | NISSAN CHEMICAL IND LTD (JP) | 2017-06-14 | — | — | EP | claimed |
| US-8822127-B2 | Photosensitive resin composition for black matrix | LG CHEM, LTD. (KR) | 2014-09-02 | — | — | US | claimed |
| US-20110151379-A1 | BLACK MATRIX COMPOSITION WITH HIGH LIGHT-SHIELDING AND IMPROVED ADHESION PROPERTIES | LG CHEM, LTD. (KR) | 2011-06-23 | — | — | US | claimed |
| US-20030073654-A1 | Stabilized transient gene expression | GENESPAN CORPORATION | 2003-04-17 | — | — | US | claimed |
| EP-1084237-A1 | STABILIZED TRANSIENT GENE EXPRESSION | Genespan Corporation (US) | 2001-03-21 | — | — | EP | claimed |
| US-6146847-A | INTRODUCING FOREIGN DNA INTO CELL; CONTACTING BEFORE, DURING, OR AFTER WITH BIOCOMPATIBLE EXPRESSION ENHANCING AGENT WHICH IS NOT BUTYRATE OR BUTYRIC ACID; MAINTAINING IN NON-SELECTIVE MEDIUM; AFTER 5 DAYS, DETECTING FOREIGN PROTEIN | GENESPAN CORPORATION (US) | 2000-11-14 | — | — | US | claimed |
| WO-1999064578-A1 | STABILIZED TRANSIENT GENE EXPRESSION | GENESPAN CORPORATION (US) | 1999-12-16 | — | — | WO | claimed |
| US-20240238325-A1 | Artificial Nucleic Acid and Method for Delivery of Nucleic Acid Using the Same | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240024486-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE COMPRISING A POLYMER IN THE FORM OF A PULVERULENT SOLID AS THICKENING AGENT | SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC (FR) | 2024-01-25 | — | — | US | disclosed |
| US-20240026078-A1 | Polymer taking the form of a pulverulent solid and having properties for thickening polar media | SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC (FR) | 2024-01-25 | — | — | US | disclosed |
| US-20240026250-A1 | LIQUID DETERGENT COMPOSITION FOR HOUSEHOLD OR INDUSTRIAL USE COMPRISING A POLYMER IN THE FORM OF A PULVERULENT SOLID AS THICKENING AGENT | SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC (FR) | 2024-01-25 | — | — | US | disclosed |
| US-10716795-B2 | Steroid analogues for neuroprotection | EMORY UNIVERSITY (US) | 2020-07-21 | — | — | US | disclosed |
| EP-2609426-B1 | FLUORESCENCE LABELING REAGENTS AND USES THEREOF | TEXAS A & M UNIV SYS (US) | 2018-12-19 | — | — | EP | disclosed |
| EP-1420021-A1 | DNA Methyltransferase inhibitors | The Penn State Research Foundation (US) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003061550-A2 | NOVEL CATALYTIC ACTIVITIES OF OXIDOREDUCTASES FOR OXIDATION AND/OR BLEACHING | CALL, KRIMHILD (DE) | 2003-07-31 | — | — | WO | disclosed |
| WO-2002099023-A2 | ENZYMATIC SYSTEMS FOR GENERATING ACTIVE OXYGEN SPECIES FOR REACTING WITH OTHER PRECURSORS TO OBTAIN OXIDATION AND/OR BLEACHING | CALL, KRIMHILD (DE) | 2002-12-12 | — | — | WO | disclosed |
| EP-1181291-A2 | DNA METHYLTRANSFERASE INHIBITORS | THE PENN STATE RESEARCH FOUNDATION (US) | 2002-02-27 | — | — | EP | disclosed |
| WO-2000075142-A2 | DNA METHYLTRANSFERASE INHIBITORS | THE PENN STATE RESEARCH FOUNDATION (US) | 2000-12-14 | — | — | WO | disclosed |
| EP-1012376-A2 | OXIDATION AND BLEACHING SYSTEM WITH ENZYMATICALLY PRODUCED OXIDIZING AGENTS | Blume, Hildegard (DE) | 2000-06-28 | — | — | EP | disclosed |
| WO-1998059108-A2 | OXIDATION AND BLEACHING SYSTEM WITH ENZYMATICALLY PRODUCED OXIDIZING AGENTS | BLUME, HILDEGARD (DE) | 1998-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073654-A1 | Stabilized transient gene expression | MYC, FIBP, SLC2A8 | CA2 3801/4885MAPK1 4215/4885CHRM1 4816/4885 |
| US-20240026078-A1 | Polymer taking the form of a pulverulent solid and having properties for thickening polar media | PGAM1, GLUL, SGTA | CA2 1087/4885MAPK1 3239/4885CHRM1 185/4885 |
| US-20240238325-A1 | Artificial Nucleic Acid and Method for Delivery of Nucleic Acid Using the Same | HNRNPH3, RNASEH1, HNRNPA1 | CA2 1755/4885MAPK1 3438/4885CHRM1 2724/4885 |
| US-10716795-B2 | Steroid analogues for neuroprotection | CYP11A1, NR3C2, HSD17B7 | CA2 4563/4885MAPK1 2406/4885CHRM1 1514/4885 |
| US-20240024486-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE COMPRISING A POLYMER IN THE FORM OF A PULVERULENT SOLID AS THICKENING AGENT | PGA5, SGTA, GYPA | CA2 867/4885MAPK1 4548/4885CHRM1 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.